{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069254","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.149042+00:00","generated_at":"2026-05-22T00:28:10.258203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ProKidney Q1 net loss $38M; cash $328.5M; REGEN-007 data due Q2 2025","bullets":["Net loss before noncontrolling interest was $38.0M for Q1 2025 vs $35.3M in Q1 2024.","Cash, cash equivalents and marketable securities totaled $328.5M as of March 31, 2025, funding operations into mid-2027.","Full data from Group 1 of Phase 2 REGEN-007 study expected in Q2 2025 (approx. 20 patients, ~18 months follow-up).","FDA confirmed accelerated approval pathway for rilparencel in Q4 2024; details expected mid-2025 after Type B meeting.","R&D expenses flat at $27.3M; G&A increased to $14.4M from $12.8M in prior-year period."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069254","json":"https://secwatch.observer/filing/0000950170-25-069254.json","markdown":"https://secwatch.observer/filing/0000950170-25-069254.md","text":"https://secwatch.observer/filing/0000950170-25-069254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/0000950170-25-069254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/prok-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:28:10.258203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}